Exelixis puts fat wallet to work with Cybrexa, Sairopa deals - San Francisco Business Times

Exelixis Inc. President and CEOwarned that the company wasn't going to just sit on its cancer drug franchise, not with $2 billion in cash, equivalents and investments.

In the Sairopa deal, Exelixis will pay $40 million upfront and $70 million in near-term milestones for an exclusive, worldwide license to develop and sell Sairopa's ADU-1805. The drug is a monoclonal antibody targeting a protein — called signal regulatory protein alpha, or SIRPa — that protects cancer-associated proteins from being detected by the immune system's T cells and helps block the ability to clear tumor cells.

The moves were announced as Exelixis reported its third-quarter financials that showed the company with a $212.4 million profit through the first nine months of the year on revenue of nearly $1.19 billion.

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

An inside look into multi-family housing and the real estate market today - CEO SpotlightShakti C'Ganti, CEO, Ashland Greene Capital joins KRLD's David Johnson for this episode of CEO Spotlight.
Fonte: KRLD - 🏆 75. / 68 Consulte Mais informação »

Orlando Tijuana Flats names restaurant veteran its new CEO - Jacksonville Business JournalHe replaces Brian Wright, who left after nearly four years with the company.
Fonte: JaxBizJournal - 🏆 599. / 51 Consulte Mais informação »